Molecular Profile Detail

Profile Name MET D1228N
Gene Variant Detail

MET D1228N (gain of function)

Relevant Treatment Approaches MET Inhibitor

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Relevant Treatment Approaches Therapy Name Approval Status Evidence Type Efficacy Evidence References
MET D1228N Advanced Solid Tumor predicted - sensitive MET Inhibitor Cabozantinib Preclinical Actionable In a preclinical study, transformed cells expressing mouse MET D1226N (corresponds to MET D1228N in humans) were sensitive to treatment with Cometriq (Cabometyx, cabozantinib), demonstrating inhibition of cell growth in culture and tumor growth inhibition in mouse models (PMID: 28396313). 28396313
MET D1228N Advanced Solid Tumor predicted - sensitive MET Inhibitor BMS-777607 Preclinical - Cell culture Actionable In a preclinical study, transformed cells expressing mouse MET D1226N (corresponds to D1228N in humans) were sensitive to treatment with BMS-777607 (ASLAN002), demonstrating inhibition of cell growth in culture (PMID: 28396313). 28396313
MET D1228N Advanced Solid Tumor predicted - resistant MET Inhibitor Capmatinib Preclinical Actionable In a preclinical study, transformed cells expressing mouse MET D1226N (corresponds to MET D1228N in humans) were resistant to treatment with Capmatinib (INC280), demonstrating sustained cell growth in culture and minimal tumor growth inhibition in mouse models (PMID: 28396313). 28396313
MET D1228N Advanced Solid Tumor predicted - resistant MET Inhibitor Crizotinib Preclinical Actionable In a preclinical study, transformed cells expressing mouse MET D1226N (corresponds to MET D1228N in humans) were resistant to treatment with Xalkori (crizotinib), demonstrating sustained cell growth in culture and minimal tumor growth inhibition in mouse models (PMID: 28396313). 28396313
MET D1228N Advanced Solid Tumor predicted - sensitive MET Inhibitor Altiratinib Preclinical Actionable In a preclinical study, Altiratinib (DCC-2701) inhibited activity of MET D1228N in an in vitro kinase assay (PMID: 26285778). 26285778
MET D1228N Advanced Solid Tumor predicted - resistant MET Inhibitor Savolitinib Preclinical - Cell culture Actionable In a preclinical study, transformed cells expressing mouse MET D1226N (corresponds to MET D1228N in humans) were resistant to treatment with Savolitinib (AZD6094), demonstrating sustained cell growth in culture (PMID: 28396313). 28396313
MET D1228N Advanced Solid Tumor sensitive MET Inhibitor Merestinib Preclinical - Cell culture Actionable In a preclinical study, Merestinib (LY2801653) inhibited growth of transformed cells over expressing MET D1228N in culture (PMID: 23275061). 23275061
Clinical Trial Phase Therapies Title Recruitment Status